2 completed. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow Arshad Khanani: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs Aflibercept in Patients With DME Ranibizumab 0.3 mg, Aflibercept 2.0 mg - Diabetic Macular Edema | Phase 2 | Completed | Arshad Khanani | 101 | 2015-01-01 | 2019-04-26 |
| Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration Ranibizumab 0.5mg, Aflibercept 2.0mg - Neovascular Age-Related Macular Degeneration | Phase 1 / Phase 2 | Completed | Arshad Khanani | 100 | 2013-09-01 | 2016-03-03 |
Ranibizumab (2) · aflibercept (2)
United States (2)